Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates

摘要

Gajardo and colleagues1 contend that our finding of continued increased prevalence of parvovirus B19 (B19V) antibodies among users of plasma-derived factor concentrates relative to people with bleeding disorders unex-posed to any blood or factor product2 may have been influenced by exposure to product not subjected to B19V nucleic acid test (NAT) screening or to exposure to low-purity products during the study period. The authors also disagree with our characterization of B19V as resistant to viral inactivation steps used in the manufacture of antihe-mophilic factor concentrates.